Table 2.
Non-randomized prospective series (n > 40) assessing biological outcome of localized prostate cancer treated with stereotactic body radiation therapy (SBRT).
| NCCN Risk Groups (%) | bRFS (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors | n | LR | IR | HR | Gy/fx | ADT (%) | FU (y) | 2–3y | 5y |
| Madsen 2007 [73] | 40 | 100 | 0 | 0 | 33.5/5 | NR | 3.4 | 90.0 | |
| Friedland 2009 [74] | 112 | NR | NR | NR | 35–36/5 | 19 | 2.0 | 97.4 | |
| Kang 2011 [75] | 44 | 11 | 23 | 66 | 32–36/4 | 89 | 3.3 | 100 a 96.0 b |
100 a 90.9 b |
| Mc Bride 2012 [76] | 45 | 100 | 0 | 0 | 36.25–37.5/5 | 0 | 3.7 | 97.7 | |
| King 2012 [77] | 67 | 100 | 0 | 0 | 36.25/5 | 0 | 2.7 | 100 | 94.0 |
| Aluwini 2013 [78] | 50 | 60 | 40 | 0 | 38/4 | 0 | 1.9 | 100 | |
| Chen 2013 [79] | 100 | 37 | 55 | 8 | 35–36.25/5 | 11 | 2.3 | 99.0 | |
| Bolzicco 2013 [80] | 100 | 41 | 42 | 17 | 35/5 | 29 | 3.0 | 96.0 | 94.4 |
| Loblaw 2013 [81] | 84 | 100 | 0 | 0 | 35/5 | 0 | 4.6 | 100 | 98.0 |
| Oliai 2013 [82] | 70 | 51 | 31 | 17 | 35–37.5/5 | 33 | 2.6 | 94.5 | |
| Lee 2014 [83] | 45 | 13 | 58 | 29 | 36/5 | 38 | 5.2 | ~95.0 | 89.7 |
| Mantz 2014 [84] | 102 | 100 | 0 | 0 | 40/5 | NR | 5.0 | 100 | 100 |
| Fuller 2014 [27] | 79 | 51 | 49 | 0 | 38/4 | NR | 5.0 | 100 | 95 |
| Bernetich 2014 [85] | 142 | 43 | 44 | 13 | 35–37.5/5 | 28 | 3.3 | 95.5 | 92.7 |
| Davis 2015 [86] | 437 | 43 | 49 | 8 | 35–38/4–5 | 11 | 1.7 | 96.1 | |
| Freeman 2015 [87] | 1743 | 41 | 42 | 10 | 35–40/4–5 | NR | 2.0 | 92.0 | |
| Rana 2015 [88] | 102 | 36 | 55 | 8 | 36.25/5 | 9 | 4.3 | 100 | |
| Hannan 2016 [89] | 91 | 36 | 64 | 0 | 45–50/5 | 17 | 4.5 | 100 | 98.6 |
| D’Agostino 2016 [90] | 90 | 59 | 41 | 0 | 35/5 | 13 | 2.3 | 97.8 | |
| Rucinska 2016 [91] | 68 | 10 | 90 | 0 | 33.5/5 | 77 | 2.0 | 100 | |
| Katz 2016 [92] | 515 | 63 | 30 | 7 | 35–36.25/5 | 14 | 7.0 | 98.0 a 72.0 b |
94.7 a 68.6 b |
| Dixit 2017 [93] | 45 | 24 | 62 | 13 | 36.25/5 | 16 | 1.5 | 100 | |
| Miszczyk 2017 [94] | 400 | 53 | 47 | 0 | 36.25/5 | 58 | 1.3 | 99.5 | |
| Koskela 2017 [95] | 218 | 22 | 27 | 51 | 35–36/5 | 65 | 1.9 | ~97.0 a 92.8 b |
|
| Jackson 2018 [96] | 66 | 49 | 51 | 0 | 37/5 | 0 | 3.0 | 100 | |
| Alayed 2018 [97] | 84 30 |
100 60 |
0 40 |
0 0 |
35/5 40/5 |
1 0 |
9.6 6.9 |
100 100 |
97.5 96.7 |
| Meier 2018 [98] | 309 | 172 | 137 | 0 | 40/5 | 0 | 5.1 | 97.1 | |
LR = low risk; IR = intermediate risk; HR = high risk; Gy = prescription dose in Gray, fx = number of fractions; bRFS = biochemical recurrence-free survival; ADT = androgen deprivation therapy; FU = median follow-up. When a significant subpopulation (n ≥ 30) of HR patients was available, results were split between LR/IR a and HR b.